Back to top
more

Avanos Medical (AVNS)

(Real Time Quote from BATS)

$11.23 USD

11.23
39,728

+0.25 (2.28%)

Updated Aug 4, 2025 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intuitive Surgical (ISRG) Gains Following Q1 Earnings Beat

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.

Zacks Equity Research

Elevance Health (ELV) Beats on Q1 Earnings, Hikes Profit View

by Zacks Equity Research

Elevance Health's (ELV) first-quarter results reflect growing premiums stemming from rate increases.

Zacks Equity Research

Here's Why You Should Buy Boston Scientific (BSX) Stock

by Zacks Equity Research

Investors are optimistic about Boston Scientific (BSX) owing to impressive growth in MedSurg market share.

Zacks Equity Research

Abbott's (ABT) Q1 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Double-digit organic growth in Diabetes Care, Structural Heart, Heart Failure and Neuromodulation contributed to Abbott's (ABT) Q1 revenues.

Zacks Equity Research

Myriad Genetics (MYGN) Gets Permit to Expand Tumor Testing

by Zacks Equity Research

Myriad Genetics (MYGN) and Intermountain Precision Genomics receive the New York State Clinical Laboratory Permit to offer solid tumor testing to patients in all 50 U.S. states.

Zacks Equity Research

Insulet's (PODD) New Omnipod, Strategic Moves Drive Growth

by Zacks Equity Research

Insulet (PODD) has been progressing well with respect to its four-pillar strategy, where the first two pillars include expanding access and awareness and delivering consumer-focused innovation.

Zacks Equity Research

Here's Why You Should Invest in Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), led by the strong potential in the company's dental technology joint venture, Henry Schein One.

Zacks Equity Research

Abbott (ABT) Gets FDA Clearance for FreeStyle Libre 3 Reader

by Zacks Equity Research

Abbott (ABT) receives the FDA clearance for a standalone reader to be used for the FreeStyle Libre 3 iCGM system.

Zacks Equity Research

UnitedHealth (UNH) Beats on Q1 Earnings, Ups EPS 2023 View

by Zacks Equity Research

Strong membership growth and consistent management of medical and operating costs aid UnitedHealth's (UNH) UnitedHealthcare unit in the first quarter.

Zacks Equity Research

Bio-Rad (BIO) Rises 6.5% Since Q4 Earnings: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Bio-Rad's (BIO) strong global presence and stable solvency position.

Zacks Equity Research

Globus' (GMED) NUVA Buyout Seems Strategic, Cost Woe Stays

by Zacks Equity Research

Globus Medical (GMED) and NuVasive (NUVA) are currently planning to combine in an all-stock transaction to create a global musculoskeletal company.

Zacks Equity Research

Amedisys (AMED) New Buyouts Aid Growth, CMS Ruling Unfavorable

by Zacks Equity Research

For Amedisys (AMED), dealing with the continuous shortage of clinical labo, in nursing in particular, has been challenging.

Zacks Equity Research

Walgreens (WBA) Declares Partnership With Prothena Corporation

by Zacks Equity Research

Walgreens (WBA) collaborates with Prothena Corporation to support patient awareness, participation and representation in a clinical trial of Prothena's Alzheimer's drug candidate, PRX012.

Zacks Equity Research

Myriad Genetics' (MYGN) New Pact to Boost Precision Medicine

by Zacks Equity Research

Myriad Genetics' (MYGN) latest program will increase access to affordable genetic testing. It will also aid in identifying and elevating high-risk patient care.

Zacks Equity Research

Are Investors Undervaluing Avanos Medical (AVNS) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

BRKR's Canopy Biosciences Partners With Enable Medicine

by Zacks Equity Research

BRKR's Canopy Biosciences collaborates with Enable Medicine to bring advanced spatial analysis pipelines to the Canopy CellScape System for high-plex spatial biology.

Zacks Equity Research

Brookdale (BKD) Q1 Adjusted EBITDA to Beat View, Occupancy Up

by Zacks Equity Research

Brookdale Senior Living (BKD) witnesses 17 straight months of year-over-year increases in weighted average occupancy level.

Zacks Equity Research

Illumina (ILMN) Partners With Henry Ford Health for NGS Test

by Zacks Equity Research

Illumina (ILMN) collaborates with Henry Ford Health to conduct a series of studies that is likely to focus on the genetic drivers of cardiovascular disease.

Zacks Equity Research

Here's Why Investors Should Buy Bio-Rad (BIO) Stock Now

by Zacks Equity Research

Investors are optimistic about Bio-Rad (BIO) on robust growth in Life Science and Clinical Diagnostics arms.

Zacks Equity Research

Thermo Fisher (TMO) Expands to Boost Commercial Manufacturing

by Zacks Equity Research

Thermo Fisher's expansion in Bourgoin is built on the company's investments in small molecule solutions.

Zacks Equity Research

Henry Schein (HSIC) Acquires Majority Stake in Biotech Dental

by Zacks Equity Research

Henry Schein (HSIC) announces that the completion of the Biotech Dental partnership brings forth the company's several important solutions to customers.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) strength in the Companion Animal Group business.

Zacks Equity Research

CVS Health (CVS) Team Up to Treat Digestive Disorder Virtually

by Zacks Equity Research

CVS Health's (CVS) recent partnership with Oshi makes it possible for its members to receive coordinated virtual digestive treatment.

Zacks Equity Research

Reasons to Retain ShockWave Medical (SWAV) in Your Portfolio

by Zacks Equity Research

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Zacks Equity Research

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.